[Skip to Content]
[Skip to Content Landing]
Article
November 1989

Interleukin 2 Receptor Expression in Patients With Head and Neck Squamous Carcinoma: Effects of Thymosin α1 In Vitro

Author Affiliations

From the Departments of Otolaryngology-Head and Neck Surgery (Dr Wolf and Mss Peterson and Poore) and Pathology (Drs Hudson and McClatchey), University of Michigan and Veterans Administration Medical Center, Ann Arbor.

Arch Otolaryngol Head Neck Surg. 1989;115(11):1345-1349. doi:10.1001/archotol.1989.01860350079019
Abstract

• Altered cellular immunity in patients with advanced head and neck cancer includes impairments in lymphokine production, blastogenesis, in vitro cytotoxicity, and T-cell levels. Recent evidence for the potential importance of in vivo cytotoxicity mediated by the lymphokine interleukin 2 (IL-2) in patients with cancer prompted a study of the kinetics of IL-2 receptor expression on lymphocytes from patients with untreated advanced head and neck cancer and normal subjects and an evaluation of the in vitro effects of the T-cell immune-reconstituting peptide, thymosin α1. Concanavalin A—stimulated IL-2 receptor expression was maximal after 72 hours and was higher in normal subjects than in patients. This was due to lower levels of helper/inducer (CD4) cells

×